Literature DB >> 1607662

Induction of a cellular immune response to a foreign antigen by a recombinant Listeria monocytogenes vaccine.

R Schafer1, D A Portnoy, S A Brassell, Y Paterson.   

Abstract

A recombinant strain of Listeria monocytogenes that stably and constitutively expresses Escherichia coli beta-galactosidase was used as a live vaccine vector. BALB/c mice were immunized orally or parenterally with the recombinant L. monocytogenes, and their cellular and humoral immune responses to beta-galactosidase were measured. Spleen cells taken 1 week after oral inoculation or 5 weeks after oral or parenteral inoculation (with a boost at 4 weeks) showed beta-galactosidase-specific CTL responses. The CTL line derived from mice immunized i.p. was also shown to be class I restricted and Thy-1.2+, CD8+, and TCR alpha beta+. All mice immunized with the recombinant L. monocytogenes had positive delayed-type hypersensitivity responses to heat-killed L. monocytogenes, but only 15% had a positive delayed-type hypersensitivity reaction to beta-galactosidase. Individual serum samples from mice immunized i.p. or i.v. were tested for antibody to beta-galactosidase. Approximately 11% had low positive titers for beta-galactosidase antibodies. These results demonstrate that both oral and parenteral immunization with recombinant L. monocytogenes results in a cellular immune response to the foreign protein, which is primarily a specific CD8+ CTL response.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1607662

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  31 in total

1.  Listeria monocytogenes: at the coalface of host-pathogen research.

Authors:  Conor O'Byrne; Marta Utratna
Journal:  Bioeng Bugs       Date:  2010 Nov-Dec

Review 2.  Enteric pathogens as vaccine vectors for foreign antigen delivery.

Authors:  Camille N Kotton; Elizabeth L Hohmann
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

Review 3.  Listeria and Salmonella bacterial vectors of tumor-associated antigens for cancer immunotherapy.

Authors:  Yvonne Paterson; Patrick D Guirnalda; Laurence M Wood
Journal:  Semin Immunol       Date:  2010-03-17       Impact factor: 11.130

Review 4.  The next wave of recombinant and synthetic anticancer vaccines.

Authors:  K R Irvine; N P Restifo
Journal:  Semin Cancer Biol       Date:  1995-12       Impact factor: 15.707

5.  Recombinant Listeria monocytogenes vaccination eliminates papillomavirus-induced tumors and prevents papilloma formation from viral DNA.

Authors:  E R Jensen; R Selvakumar; H Shen; R Ahmed; F O Wettstein; J F Miller
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

6.  Enhanced immunoglobulin A response and protection against Salmonella enterica serovar typhimurium in the absence of the substance P receptor.

Authors:  Nancy Walters; Theresa Trunkle; Michael Sura; David W Pascual
Journal:  Infect Immun       Date:  2005-01       Impact factor: 3.441

7.  Existing antilisterial immunity does not inhibit the development of a Listeria monocytogenes-specific primary cytotoxic T-lymphocyte response.

Authors:  H G Bouwer; H Shen; X Fan; J F Miller; R A Barry; D J Hinrichs
Journal:  Infect Immun       Date:  1999-01       Impact factor: 3.441

8.  Conditional lethality yields a new vaccine strain of Listeria monocytogenes for the induction of cell-mediated immunity.

Authors:  Zhongxia Li; Xinyan Zhao; Darren E Higgins; Fred R Frankel
Journal:  Infect Immun       Date:  2005-08       Impact factor: 3.441

9.  Cancer immunotherapy targeting the high molecular weight melanoma-associated antigen protein results in a broad antitumor response and reduction of pericytes in the tumor vasculature.

Authors:  Paulo Cesar Maciag; Matthew M Seavey; Zhen-Kun Pan; Soldano Ferrone; Yvonne Paterson
Journal:  Cancer Res       Date:  2008-10-01       Impact factor: 12.701

10.  Cholera toxin acts as a potent adjuvant for the induction of cytotoxic T-lymphocyte responses with non-replicating antigens.

Authors:  J C Bowen; S K Nair; R Reddy; B T Rouse
Journal:  Immunology       Date:  1994-03       Impact factor: 7.397

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.